Table 1.

Study characteristics

	Augustus	Re‐Dual PCI	Pioneer AF‐PCI	Entrust AF PCI
Patients (n)	2307	1527	1393	1506
Study design	P2Y12 inhibitor + Apixaban or VKA + aspirin or placebo for 6 months	Dual therapy with dabigatran (150 mg) +P2Y12 inhibitor or triple therapy with warfarin + aspirin +P2Y12 inhibitor for 12 months	Group 1: Rivaroxaban (15 mg) + SAPT (P2Y12 inhibitor) for 12 months inhibitor) Group 3: VKA + DAPT (aspirin + P2Y12 inhibitor)	Edoxaban + SAPT (P2Y12 inhibitor) for 12 months or VKA + DAPT (P2Y12 inhibitor + aspirin) for 1 to 12 months
Blinding	Placebo‐controlled	Open‐label	Open‐label	Open‐label
Time to randomization	14 days	5 days	3 days	5 days
Primary outcome	Major or CRNM bleeding at 6 months	Major or CRNM bleeding at 12 months	Clinically relevant bleeding at 12 months	Major or CRNM bleeding at 12 months
Treatment effect for intervention vs control	HR 0.53, 95% CI 0.45‐0.63, P < .001 for superiority	HR 0.72,95% CI 0.58‐0.88, P = .002 for superiority (dabigatran 150 mg bid)	HR 0.59, 95% CI 0.47‐0.76, P < .001 for superiority	HR 0.83, 95% CI 0.65‐1.05, P = .001 for noninferiority, P = .1154 for superiority
Year	2019	2017	2016	2019
Follow‐up	6 months	14 months	12 months	12 months